LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
This test is a component of Primary Biliary Cirrhosis Profile (PBC).
7 - 14 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
0.5 mL (Note: This volume does not allow for repeat testing.)
Red-top tube or gel-barrier tube
Separate serum from cells within one hour of collection. Transfer to a plastic transport tube before shipping. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Refrigerate or freeze.
Grossly hemolyzed; bacterial contamination; lipemic specimen; icteric specimen; non-serum specimen types
Primary biliary cirrhosis (PBC) is an organ-specific autoimmune disease that predominantly affects women and is characterized by chronic progressive destruction of small intrahepatic bile ducts with portal inflammation and ultimately fibrosis. PBC affects more than men (female:male ratio of 1:9) and typically occurs between the ages of 30 and 65. The prevalence of PBC in first-degree relatives of PBC patients range is from 1.3 to 6.4%. Serologic assays are important aids to the recognition and diagnosis of PBC since many antibodies associated with PBC are present before symptoms become evident. Anti-gp210 and/or sp100 antibodies can be detected in approximately 25% of all PBC patients and 30% of AMA-negative PBC patients. The gp210 and sp100 antibodies have a relatively low sensitivity, but the specificity is greater than 99%. Additionally, the antibodies may identify a subgroup of patients with a more severe disease course. The gp210 and sp100 EIA will provide clinicians with additional serological markers for detection of PBC and may help earlier identification, diagnosis, and treatment of patients negative for conventional markers of PBC. Combined testing for three markers (M2, gp210 and sp100) identified 92% of PBC patients.
Enzyme-linked immunosorbent assay (ELISA)
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf